Loss of p27 expression through RAS→BRAF→MAP kinase-dependent pathway in human thyroid carcinomas

Cell Cycle

Volumn 6, Issue 22, 2007, Pages 2817-2825

  Motti, Maria Letizia ^a   De Marco, Carmela ^b   Califano, Daniela ^c   De Gisi, Silvia ^d,e   Malanga, Donatella ^d,e   Troncone, Giancarlo ^b   Persico, Angela ^c   Losito, Simona ^c   Fabiani, Fernanda ^d   Santoro, Massimo ^b   Chiappetta, Gennaro ^c   Fusco, Alfredo ^b   Viglietto, Giuseppe ^d,e  

^a UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e Grande Ospedale Metropolitano   (Italy)

Author keywords

MAP kinase; Oncogene; p27; SKP2; Thyroid cancer

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN P27; PROTEIN PATCHED 1; PROTEIN RET; RAS PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2;

ARTICLE; CANCER CELL; CANCER MODEL; CARCINOGENESIS; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE; PROTEIN STABILITY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; THYROID CARCINOMA;

EID: 37249061098     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.22.4883     Document Type: Article

References (79)

1. Malumbres M, Barbacid M. To cycle or not to cycle: A critical decision in cancer. Nat Rev Cancer 2001; 1:222-31.
2. Sherr CJ. Cancer cell cycles. Science 1996; 274:1672-7.
3. 1-phase progression. Genes Dev 1999; 13:1501-12.
4. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002; 1602:73-87.
5. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994; 8:9-22.
6. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78:59-66.
7. Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci USA 1994; 9:5291-5.
8. Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol 1994; 14:3683-94.
9. Sa G, Guo Y, Stacey DW. The regulation of S phase initiation by p27Kip1 in NIH3T3 cells. Cell Cycle 2005; 4:618-27.
10. Gitomi M, Yang K, Guo Y, Fretthold J, Harwalkar J, Stacey DW. p27Kip1 and cyclin dependent kinase 2 regulate passage through the restriction point. Cell Cycle 2006; 5:2281-9.
11. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996; 85:733-4.
12. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996; 85:707-20.
13. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996; 85:721-32.
14. kip1 deregulation in cancer: Down-regulation or mislocalization? Cell Cycle 2002; 1:394-400.
15. Blain SW, Massague J. Breast cancer banishes p27 from nucleus. Nat Med 2002; 8:1076-8.
16. Kip1 and its deregulation in cancer. J Cell Physiol 2000; 183:10-17.
17. Kip1 and its alterations in tumor cells: A review. J Cell Physiol 2000; 183:18-27.
18. Kip1 protein: Prognostic implications in primary breast cancer. Nat Med 1997; 3:227-230.
19. Kip1 in aggressive colorectal carcinomas. Nat Med 1997; 3:231-4.
20. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27Kip1 in non-small cell lung cancer. Cancer Res 1997; 57:3381-5.
21. Kip1. Genes Dev 1997; 11:1464-78.
22. Kip1. EMBO J 1997; 16:5334-44.
23. Kip1. Nat Cell Biol 1999; 1:193-9.
24. Kip1. Science 1995; 269:682-5.
25. kip1 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999; 13:1181-9.
26. kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 1998; 11:169-74.
27. Kip1 in the cytoplasm of thyroid tumor cells. J Clin Invest 1999; 104:865-74.
28. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006; 6:292-306.
29. Tallini G. Molecular pathobiology of thyroid neoplasms. Endocr Pathol 2002; 13:271-88.
30. Hedinger C, Williams ED, Sobin LH. Histologycal Typing of Thyroid Tumors. Heidelberg: Springer-Verlag, 1988:908-11.
31. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J, Santoro M. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005; 65:10199-207.
32. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411:355-5.
33. Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med 2006; 38:200-11.
34. Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 2005; 5:350-6.
35. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996; 271:20608-16.
36. Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 1997; 15:629-37.
37. Ohta K, Pang XP, Berg L, Hershman JM. Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor. J Clin Endocrinol Metab 1997; 82:2633-8.
38. Pang XP, Hershman JM, Chung M, Pekary AE. Characterization of tumor necrosis factor-alpha receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin. Endocrinology 1989; 125:245-9.
39. Tanaka J, Ogura T, Sato H, Hatano M. Establishment and biological characterization of an in vitro human cytomegalovirus latency model. Virology 1987; 161:62-72.
40. Estour B, Van Herle AJ, Juillard GJ, Totanes TL, Sparkes RS, Giuliano AE, Klandorf H. Characterization of a human follicular thyroid carcinoma cell line (UCLA RO 82 W-1). Virchows Arch B Cell Pathol Incl Mol Pathol 1989; 57:167-74.
41. Fiore L, Pollina LE, Fontanini G, Casalone R, Berlingieri MT, Giannini R, Pacini F, Miccoli P, Toniolo A, Fusco A, Basolo F. Cytokine production by a new undifferentiated human thyroid carcinoma cell line, FB-1. J Clin Endocrinol Metab 1997; 82:4094-100.
42. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffer HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993; 91:179-84.
43. Troncone G, Iaccarino A, Russo M, Palmieri EA, Volante M, Papotti M, Viglietto G, Palombini L. Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma. J Clin Pathol 2007; 60:377-81.
44. Viglietto G, Chiappetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, Rigopoulou D, Visconti R, Mastro A, Santoro M, Fusco A. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 1995; 11:1207-10.
45. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54.
46. Di Cristofaro J, Marcy M, Vasko V, Sebag F, Fakhry N, Wynford-Thomas D, De Micco C. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: Association of N-ras mutation in codon 61 with follicular variant. Hum Pathol 2006; 37:824-30.
47. Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortes-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS, Goldhirsch A. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: Results from International Breast Cancer Study Group Trial V. Cancer 2003; 97:1591-600.
48. Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, Carbone A, Cittadini A, Mancuso S, Scambia G, Giordano A. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 1999; 59:3790-4.
49. Baldassarre G, Barone MV, Belletti B, Sandomenico C, Bruni P, Spiezia S, Boccia A, Vento MT, Romano A, Pepe S, Fusco A, Viglietto G. Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation. Oncogene 1999; 18:6241-51.
50. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159.
51. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: A Laboratory Manual II. New York: Ed. Cold Spring Harbor Laboratory Press, 1992.
52. Motti ML, Califano D, Baldassarre G, Celetti A, Merolla F, Forzati F, Napolitano M, Tavernise B, Fusco A, Viglietto G. Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis 2005; 26:1021-34.
53. Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V, Miyakawa M, Isozaki O, Murakami H, Tsushima T, Burman KD, De Micco C, Ringel MD. Akt activation and localisation correlate with tumor invasion and oncogene expression in thyroid cancer. J Med Genet 2004; 41:161-70.
54. Motti ML, Califano D, Troncone G, De Marco C, Migliaccio I, Palmieri E, Pezzullo L, Palombini L, Fusco A, Viglietto G. Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: Regulation of p27kip1 expression and localization. Am J Pathol 2005; 166:737-49.
55. Vitagliano D, Carlomagno F, Motti ML, Viglietto G, Nikiforov YE, Nikiforova MN, Hershman JM, Ryan AJ, Fusco A, Melillo RM, Santoro M. Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. Cancer Res 2004; 64:3823-9.
56. Kip1. J Biol Chem 1997; 272:32966-71.
57. Kip1 degradation through its regulation of cyclin E/CDK2 activity. J Biol Chem 1999; 274:3396-401.
58. Kip1 nuclear export. J Biol Chem 2003; 278:12443-51.
59. Foster JS, Fernando RI, Ishida N, Nakayama KI, Wimalasena J. Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. J Biol Chem 2003; 278:41355-66.
60. Kortylewski M, Heinrich PC, Kauffmann ME, Bohm M, MacKiewicz A, Behrmann I. Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells. Biochem J 2001; 357:297-303.
61. Kip1 downregulation and S phase entry in fibroblasts and epithelial cells. Am J Physiol 1999; 277:652-64.
62. Charland S, Boucher MJ, Houde M, Rivard N. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology 2001; 142:121-8.
63. kip1 degradation independently of CDK2/cyclin E in NIH 3T3 cells. J Biol Chem 2001; 276:34958-65.
64. Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci USA 1998; 95:1091-6.
65. Kip1 by two mechanisms: Ubiquitin-mediated degradation and proteolytic processing. J Biol Chem 1999; 274:13886-93.
66. 1 transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem 2001; 276:48937-43.
67. 1 and S phase. Nature 2001; 413:323-7.
68. 1 phase. Nat Cell Biol 2004; 12:1229-35.
69. Nakayama KI, Nakayama K. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol 2005; 16:323-33.
70. Chiappetta G, De Marco C, Quintiero A, Califano D, Gherardi S, Malanga D, Scrima M, Montero-Conde C, Cito L, Monaco M, Motti ML, Pasquinelli R, Agosti V, Robledo M, Fusco A, Viglietto G. Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. ERC 2007; 14:405-20.
71. Maemura M, Lino Y, Koibuchi Y, Yokoe T, Morishita Y. Mitogen-activated protein kinase cascade in breast cancer. Oncology 1999; 57:37-44.
72. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol 2002; 13:3-16.
73. Greco A, Roccato E, Pierotti MA. TRK oncogenes in papillary thyroid carcinoma. Cancer Treat Res 2004; 122:207-19.
74. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95:625-7.
75. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12:245-62.
76. Ciampi R, Jeffrey A, Knauf JA, Rabes HM, Fagin JA, Nikiforov YE. BRAF kinase activation via chromosomal rearrangement in radiation-induced and sporadic thyroid cancer. Cell Cycle 2005; 4:547-8.
77. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, Kroll TG, Nikiforov YE. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: Evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003; 88:2318-26.
78. Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 2006; 12:1785-93.
79. Bounacer A, McGregor A, Skinner J, Bond J, Poghosyan Z, Wynford-Thomas D. Mutant ras-induced proliferation of human thyroid epithelial cells requires three effector pathways. Oncogene 2004; 23:7839-45.